Relay Therapeutics to Announce Third Quarter 2024 Financial Results and Corporate Highlights on November 6, 2024
Relay Therapeutics (Nasdaq: RLAY), a clinical-stage precision medicine company, announced it will report its third quarter 2024 financial results and corporate highlights on November 6, 2024 after the U.S. financial markets close.
Relay Therapeutics (Nasdaq: RLAY), un'azienda di medicina di precisione in fase clinica, ha annunciato che riporterà i suoi risultati finanziari del terzo trimestre 2024 e i punti salienti aziendali il 6 novembre 2024 dopo la chiusura dei mercati finanziari statunitensi.
Relay Therapeutics (Nasdaq: RLAY), una empresa de medicina de precisión en etapa clínica, anunció que informará sobre sus resultados financieros del tercer trimestre de 2024 y aspectos destacados corporativos el 6 de noviembre de 2024 después del cierre de los mercados financieros de EE. UU.
릴레이 테라퓨틱스 (Nasdaq: RLAY), 임상 단계의 정밀 의학 회사,는 2024년 3분기 재무 결과 및 회사 주요 사항을 2024년 11월 6일 미국 금융 시장 폐장 후 발표할 것이라고 밝혔습니다.
Relay Therapeutics (Nasdaq: RLAY), une entreprise de médecine de précision en phase clinique, a annoncé qu'elle publiera ses résultats financiers du troisième trimestre 2024 et les points saillants de l'entreprise le 6 novembre 2024 après la fermeture des marchés financiers américains.
Relay Therapeutics (Nasdaq: RLAY), ein Unternehmen für Präzisionsmedizin in der klinischen Phase, gab bekannt, dass es seine Finanzergebnisse für das dritte Quartal 2024 sowie Unternehmens-Highlights am 6. November 2024 nach Schließung der US-Finanzmärkte bekannt geben wird.
- None.
- None.
CAMBRIDGE, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report third quarter 2024 financial results and corporate highlights after the U.S. financial markets close on Wednesday, November 6, 2024.
About Relay Therapeutics
Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. As the first of a new breed of biotech created at the intersection of complementary techniques and technologies, Relay Therapeutics aims to push the boundaries of what’s possible in drug discovery. Its Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Relay Therapeutics’ initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. For more information, please visit www.relaytx.com or follow us on Twitter.
Contact:
Megan Goulart
617-545-5526
mgoulart@relaytx.com
Media:
Dan Budwick
1AB
973-271-6085
dan@1abmedia.com
FAQ
When will Relay Therapeutics announce its third quarter 2024 financial results?
What is the stock symbol for Relay Therapeutics?
